1. A carrier for delivering a substance to extracellular matrix-producing cells in the kidney, characterized in that it contains a retinoid as an agent targeting extracellular matrix-producing cells in the kidney. The carrier according to claim 1, characterized in that the retinoid contains retinol. The carrier according to claim 1 or 2, characterized in that it has the form of a liposome and the molar ratio of retinoid to lipid contained in the liposome is from 8: 1 to 1: 4.4. A pharmaceutical composition for treating kidney fibrosis, characterized in that it contains a carrier according to any one of claims 1 to 3 and a drug for controlling the activity or growth of extracellular matrix-producing cells in the kidney. The pharmaceutical composition according to claim 4, characterized in that the drug for controlling the activity or growth of the extracellular matrix cells in the kidney is selected from the group consisting of an inhibitor of the activity or production of PAI-1, an inhibitor of cell activity, a growth inhibitor, an apoptosis inducer and an RNAi molecule , ribozyme, antisense nucleic acid or DNA / RNA of a chimeric polynucleotide that targets at least one of the molecules that make up the extracellular matrix, or molecules involved in the production of the formation or secretion of the molecules that make up the extracellular matrix, or the vector expressing them. 6. The pharmaceutical composition according to claim 4, characterized in that the drug for controlling the activity or growth of extracellular matrix producing cells is an HSP47.7 inhibitor. A pharmaceutical composition according to any one of claims 4 to 6, characterized in that the drug and carrier are mixed in place to treat1. Носитель для доставки вещества к продуцирующим внеклеточный матрикс клеткам в почке, отличающийся тем, что он содержит ретиноид в качестве агента, нацеливающего на продуцирующие внеклеточный матрикс клетки в почке.2. Носитель по п.1, отличающийся тем, что ретиноид
